Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company specializes in using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with the oncology medicines most likely to work for them. This groundbreaking approach integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, known as OncoSignature companion diagnostics, for identifying patient responders.
The company's leading candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2. This drug is currently in a potentially registrational Phase 2 trial and has received Fast Track designation from the FDA for investigating its use as monotherapy for patients with platinum-resistant ovarian or endometrial cancer. The ACR-368 OncoSignature test, which is pending regulatory approval, has shown promising results in preclinical studies and past third-party Phase 2 trials.
Additionally, Acrivon is advancing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor designed using the AP3 platform. This candidate shows superior single-agent activity in preclinical studies compared to benchmark inhibitors. Acrivon plans to submit an IND for ACR-2316 in Q3 2024, with clinical study initiation expected in Q4 2024.
The company's AP3 platform not only aids in drug selection but also in rational drug design and optimization. It's engineered to measure drug effects on the tumor cell protein network, identifying resistance mechanisms and optimal drug combinations.
Recently, Acrivon has made significant strides, including FDA Breakthrough Device designation for its ACR-368 OncoSignature assay and a successful $130 million private placement financing to further fund its innovative pipeline and platform development. Acrivon's focus remains on leveraging its AP3 platform for the development of precision oncology drugs that address significant unmet medical needs, aiming to improve treatment outcomes for cancer patients worldwide.
For more updates and detailed financial information, visit Acrivon's investor relations page.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will participate in a fireside chat on May 2, 2023, at 3:00 p.m. ET during the H.C. Wainwright BioConnect Investor Conference in New York. The company focuses on developing precision oncology medicines using its proprietary proteomics-based platform, known as Acrivon Predictive Precision Proteomics (AP3). Acrivon’s leading candidate, ACR-368, targets CHK1 and CHK2 and is in a Phase 2 trial for various tumor types. The OncoSignature® companion diagnostics, although not yet regulatory approved, aim to identify patients likely to benefit from ACR-368. Acrivon also explores preclinical programs targeting other nodes in DNA Damage Response, including WEE1 and PKMYT1.
Acrivon Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ACRV), will host a virtual investor event on May 1, 2023, from 11:00 a.m. to 12:00 p.m. ET. The agenda includes a company overview, an update on the Acrivon Predictive Precision Proteomics (AP3) platform, details on the preclinical pipeline, clinical trial enrollment progress, and corporate updates.
The event can be accessed via the company’s investor website, and a replay will be available for 90 days. Acrivon focuses on precision oncology medicines, utilizing its AP3 platform for patient responder identification and developing the lead candidate ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial across various tumor types. The company is also exploring additional preclinical programs targeting critical nodes in DNA Damage Response.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that its CEO, Peter Blume-Jensen, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days Conference on April 25, 2023, at 3:00 p.m. ET. This event will be held virtually and will focus on Acrivon’s advancements in precision oncology medicines.
Acrivon’s proprietary platform, AP3, matches patients’ tumor sensitivities to specific drugs. The company is advancing its lead candidate, ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial. Acrivon also develops OncoSignature companion diagnostics to identify patients most likely to benefit from its drug candidates. A replay of the webcast will be available for 90 days after the event.
Acrivon Therapeutics (Nasdaq: ACRV) reported its financial results for Q4 and FY 2022, highlighting a net loss of $8.9 million for Q4 and $31.2 million for the full year, compared to losses of $4.3 million and $16.2 million in 2021.
The company successfully completed its IPO in November 2022 and initiated a Phase 2 trial for ACR-368 in patients with platinum-resistant cancers. Acrivon aims to advance precision oncology through its OncoSignature test and has made significant progress, including partnerships and team expansions. As of December 31, 2022, it had $169.6 million in cash, expected to fund operations through Q4 2024.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
What does Acrivon Therapeutics specialize in?
What is Acrivon's leading drug candidate?
What is the Acrivon Predictive Precision Proteomics (AP3) platform?
Has Acrivon received any regulatory designations for its drugs?
What recent achievements has Acrivon announced?
What is the status of Acrivon's ACR-2316 drug candidate?
How does the AP3 platform contribute to drug development?
What is the significance of the ACR-368 OncoSignature test?
How well-funded is Acrivon for its ongoing and future projects?
Where can investors find more information about Acrivon?
